FIELD: biotechnology.
SUBSTANCE: antibody and its antigen-binding fragment that specifically bind to GDF15 are proposed. Also nucleic acids, an expression vector and a host cell for obtaining the said antibody or fragment thereof are proposed. The invention also relates to the use of antibodies against GDF15 to reduce the level of free GDF15 or reduce the activity of GDF15 in a patient, as well as in methods of treating cancer. Including the use of a combination of an anti-GDF15 antibody of the invention and a PD-1 axis binding antagonist or an anti-CD40 antagonist antibody for the treatment of cancer.
EFFECT: invention provides new potential therapeutic anti-GDF15 antibodies.
36 cl, 34 dwg, 24 tbl, 21 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-PCSK9 ANTIBODY, ITS ANTIGEN-BINDING DOMAIN AND MEDICAL APPLICATION THEREOF | 2016 |
|
RU2739208C2 |
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
| ANTI-PD-1 ANTIBODIES | 2019 |
|
RU2788095C2 |
| ANTIBODIES B7-H4 AND METHODS FOR THEIR APPLICATION | 2019 |
|
RU2809243C2 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
| BIFUNCTIONAL PROTEINS COMBINING CHECKPOINT BLOCKADE FOR TARGETED THERAPY | 2019 |
|
RU2756899C1 |
| CD40 LIGAND THERAPEUTIC ANTIBODIES | 2018 |
|
RU2770209C2 |
| STABLE COMPOSITIONS OF ANTI-TIGIT ANTIBODIES, INDIVIDUALLY AND IN COMBINATION WITH ANTIBODIES AGAINST PROGRAMMED DEATH RECEPTOR 1 (PD-1), AND METHODS OF THEIR USE | 2018 |
|
RU2820576C2 |
| BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO PD1 AND LAG3 | 2018 |
|
RU2778805C2 |
| BISPECIFIC 2+1 ANTIBODIES | 2018 |
|
RU2797305C2 |
